Bracco International Bv

Bracco Suisse Sa

Dyax Corporation

Bracco Diagnostics Inc.

Bracco Imaging S.p.a.

E. R. Squibb Sons, Inc.

Bracco Research, USA

Tweedle, Michael F.

Nunn, Adrian D.

Strauss, Harry W.

Adrian D Nunn

Karen E Linder

Kondareddiar Ramalingam

Edmund R Marinelli

Palaniappa Nanjappan

Rolf E Swenson

Radhakrishna K Pillai

Mathew A Von Wronski

Michael F Tweedle

Bo Song

Ajay Shrivastava

Natarajan Raju

Hong Fan

Aaron Sato

Philippe Bussat

Daniel T Dransfield

Christophe Arbogast

Feng Yan

Sibylle Pochon

Sharon Michele Walker

David P Nowotnik

Richard J DiRocco

William L Rumsey

John P Pirro

Ramachandran S Ranganathan

Thangavel Arunachalam

Andrew M Schimmoeller

Paul W Wedeking

Sudha Khurana

Brian Cherundolo

Clif Moyers

Luciano Lattuada

Enrico Cappelletti

Robert Charles Ladner

Michel Schneider

Daniel J Sexton

Ruth Wager

Harry W Strauss

Ruth E Wager

Joseph Daniel Dennis, Jr

Hong (Helen) Fan

Elizabeth N Treher

Michael D Loberg

Silvia Jurisson

Thomas A Feld

James Howard McQuaid

Sybille Pochon

Nataranjan Raju

William C Eckelman

Paul Robert Steinmeyer

Christoph De Haën

Mary Ellen Maddalena

Tarah Bolas

Aaron K Sato

Richard J Di Rocco

A nuclear medicine infusion system may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame that carries a radioisotope generator that generates radioactive eluate via elution. The frame may also carry a beta detector and a gamma detector. The beta detector can be positioned to measure beta emissions emitted from the radioactive eluate supplied by the generator. The gamma detector can be positioned to measure gamma emissions emitted from a portion of the radioactive eluate to evaluate a safety of the radioactive eluate delivered by the infusion system.

Radioisotope delivery system with multiple detectors to detect gamma and beta emissions

An infusion system may include a radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to calibrate the infusion system using the gamma detector. For example, the controller may generate a radioactive eluate and measure the activity of the radioactive eluate using both the beta detector and the gamma detector. The high accuracy of the activity measured by the gamma detector may be used to calibrate the infusion system. In subsequent use, the infusion system calibrated using the gamma detector may adjust measurements made to monitor and/or control patient infusion procedures.

Systems and techniques for calibrating radioisotope delivery systems with a gamma detector

An infusion system may include a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution, a beta detector, a gamma detector, and a controller. The beta detector and the gamma detector may be positioned to measure beta emissions and gamma emissions, respectively, emitted from the radioactive eluate. In some examples, the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.

Systems and techniques for generating, infusing, and controlling radioisotope delivery

An infusion system () including a radioisotope generator () that generates a radioactive eluate via an elution, an activity detector () configured to measure an activity of a first radioisotope in the radioactive eluate generated by the radioisotope generator, and a controller (). The controller can track a cumulative volume of radioactive eluate generated by the radioisotope generator and also track the activity of the first radioisotope in the radioactive eluate generated by the radioisotope generator. The controller can determine a predicted volume of the radioactive eluate generated by the radioisotope generator at which the activity of the first radioisotope in the radioactive eluate will reach a threshold based on the tracked cumulative volume of the radioactive eluate and the tracked activity of the first radioisotope. This information can be useful for proactively removing the radioisotope generator from service and/or replacing the radioisotope generator with a fresh generator.

Early detection of radioisotope generator end life

A nuclear medicine infusion system () may be used to generate and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the infusion system includes a frame () that carries a radioisotope generator () that generates radioactive eluate via elution. The frame may also carry a beta detector () and a gamma detector (). The beta detector can be positioned to measure beta emissions emitted from the radioactive eluate supplied by the generator. The gamma detector can be positioned to measure gamma emissions emitted from a portion of the radioactive eluate to evaluate a safety of the radioactive eluate delivered by the infusion system.

A shielding assembly may be used in a nuclear medicine infusion system that generates and infuse radioactive liquid into a patient undergoing a diagnostic imaging procedure. In some examples, the shielding assembly has multiple compartments each formed of a shielding material providing a barrier to radioactive radiation. For example, the shielding assembly may have a first compartment configured to receive a radioisotope generator that generates a radioactive eluate via elution, a second compartment configured to receive a beta detector, and a third compartment configured to receive a gamma detector. In some examples, the compartments are arranged to minimize background radiation emitted by the radioisotope generator and detected by the gamma detector to enhance the quality of the measurements made by the gamma detector.

Shielding assembly for a radioisotope delivery system having multiple radiation detectors

A radioisotope generator that releases a daughter radioisotope from radioactive decay of a corresponding parent isotope, such as aSr/Rb radioisotope generator orGe/Ga radioisotope generator, may be used to generate radioisotopes for medical imaging applications. In some examples, a gamma ray detector is positioned to detect gamma rays emanating from radioactive eluate flowing from the generator. Based on the detected gamma rays, an activity of the daughter radioisotope in the eluate and an activity of the parent radioisotope in the eluate may be determined. Depending on the application, the activity of the daughter radioisotope and the activity of the parent radioisotope may be determined in substantially real time, e.g., so that the eluate can be diverted from patient dosing based on determined activity information for the eluate.

Real time nuclear isotope detection

The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K&#x3c;1 &#x3bc;M), and dimer and multimeric constructs comprising these polypeptides.

KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K&#x3c;1 &#x3bc;M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.

The invention provides compositions and methods for therapeutic and diagnostic applications.

Multivalent constructs for therapeutic and diagnostic applications

Growing community of inventors

Ringoes, NJ, United States of America

Adrian D Nunn